TY  - JOUR
A1  - Spinaci, Andrea
A1  - Lambertucci, Catia
A1  - Buccioni, Michela
A1  - Dal Ben, Diego
A1  - Graiff, Claudia
A1  - Barbalace, Maria Cristina
A1  - Hrelia, Silvana
A1  - Angeloni, Cristina
A1  - Tayebati, Seyed Khosrow
A1  - Ubaldi, Massimo
A1  - Masi, Alessio
A1  - Klotz, Karl-Norbert
A1  - Volpini, Rosaria
A1  - Marucci, Gabriella
T1  - A\(_{2A}\) adenosine receptor antagonists: are triazolotriazine and purine scaffolds interchangeable?
JF  - Molecules
N2  - The A\(_{2A}\) adenosine receptor (A\(_{2A}\)AR) is one of the four subtypes activated by nucleoside adenosine, and the molecules able to selectively counteract its action are attractive tools for neurodegenerative disorders. In order to find novel A\(_{2A}\)AR ligands, two series of compounds based on purine and triazolotriazine scaffolds were synthesized and tested at ARs. Compound 13 was also tested in an in vitro model of neuroinflammation. Some compounds were found to possess high affinity for A\(_{2A}\)AR, and it was observed that compound 13 exerted anti-inflammatory properties in microglial cells. Molecular modeling studies results were in good agreement with the binding affinity data and underlined that triazolotriazine and purine scaffolds are interchangeable only when 5- and 2-positions of the triazolotriazine moiety (corresponding to the purine 2- and 8-positions) are substituted.
KW  - A\(_{2A}\) adenosine receptor antagonist
KW  - purine derivatives
KW  - triazolotriazine derivatives
KW  - anti-Parkinson agents
KW  - anti-inflammatory agents
KW  - molecular modeling
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270618
SN  - 1420-3049
VL  - 27
IS  - 8
ER  - 
TY  - JOUR
A1  - Tan, Aaron
A1  - Babak, Maria V.
A1  - Venkatesan, Gopalakrishnan
A1  - Lim, Clarissa
A1  - Klotz, Karl-Norbert
A1  - Herr, Deron Raymond
A1  - Cheong, Siew Lee
A1  - Federico, Stephanie
A1  - Spalluto, Giampiero
A1  - Ong, Wei-Yi
A1  - Chen, Yu Zong
A1  - Loo, Jason Siau Ee
A1  - Pastorin, Giorgia
T1  - Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy
JF  - Molecules
N2  - Human A3 adenosine receptor hA3AR has been implicated in gastrointestinal cancer, where its cellular expression has been found increased, thus suggesting its potential as a molecular target for novel anticancer compounds. Observation made in our previous work indicated the importance of the carbonyl group of amide in the indolylpyrimidylpiperazine (IPP) for its human A2A adenosine receptor (hA2AAR) subtype binding selectivity over the other AR subtypes. Taking this observation into account, we structurally modified an indolylpyrimidylpiperazine (IPP) scaffold, 1 (a non-selective adenosine receptors’ ligand) into a modified IPP (mIPP) scaffold by switching the position of the carbonyl group, resulting in the formation of both ketone and tertiary amine groups in the new scaffold. Results showed that such modification diminished the A2A activity and instead conferred hA3AR agonistic activity. Among the new mIPP derivatives (3–6), compound 4 showed potential as a hA3AR partial agonist, with an Emax of 30% and EC50 of 2.89 ± 0.55 μM. In the cytotoxicity assays, compound 4 also exhibited higher cytotoxicity against both colorectal and liver cancer cells as compared to normal cells. Overall, this new series of compounds provide a promising starting point for further development of potent and selective hA3AR partial agonists for the treatment of gastrointestinal cancers.
KW  - gastrointestinal cancer
KW  - hA<sub>3</sub>AR
KW  - partial agonists
KW  - indolylpyrimidylpiperazines
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193271
SN  - 1420-3049
VL  - 24
IS  - 20
ER  -